In vitro studies have found that elevated ATP13A2 expression suppresses α-synuclein toxicity in multiple models, including rat midbrain primary dopamine neurons [2], implicating it as a potential target for PD therapeutics. This evidence concerns the gene ATP13A2 and Parkinson disease.